Palisade Bio Inc
Research Palisade Bio Inc (PALI) on Bullrun: market cap USD 359.72M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPALI
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 359.72M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 9.60M
- Free cash flow-USD 12.40M
Valuation Snapshot
latest market cap is USD 359.72M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 16.78M | -USD 10.85M | n/a | -0.3 | USD 133.39M | USD 71.00K | USD 129.38M |
| FY2024 | USD 0 | -USD 14.44M | -USD 12.19M | n/a | -10.19 | USD 9.82M | USD 169.00K | USD 7.49M |
| FY2023 | USD 250.00K | -USD 12.30M | -USD 11.14M | n/a | -27.01 | USD 12.43M | USD 369.00K | USD 11.31M |
| FY2022 | USD 0 | -USD 14.26M | -USD 13.37M | n/a | -16.53 | USD 12.38M | USD 975.00K | USD 12.48M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 359.72M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 375.16M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 4.90M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 7.24M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 23.62M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 213.53M | n/a | n/a | n/a |
About Palisade Bio Inc
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Palisade Bio Inc's market cap?
Palisade Bio Inc's market capitalization is USD 359.72M.
What does Palisade Bio Inc do?
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc.